SALICYLIC ACID

SALICYLIC ACID was reported 52632 times

SALICYLIC ACID is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BRONCHOLITHIASIS 15 0.4839
1 LICHEN NITIDUS 10 0.2857
2 ACROKERATOSIS PARANEOPLASTICA 2 0.2222
3 CHEMICAL BURN OF SKIN 533 0.2101
4 CHEMICAL PEEL OF SKIN 5 0.1724
5 SKIN IRRITATION 7728 0.1685
6 SKIN BURNING SENSATION 11556 0.1611
7 ACNE 11764 0.1550
8 SKIN FRAGILITY 332 0.1363
9 PAIN OF SKIN 3499 0.1298
10 ACNE CYSTIC 378 0.1254
11 SENSITIVE SKIN 884 0.1197
12 SEBORRHOEA 433 0.1178
13 ACNE PUSTULAR 95 0.1159
14 SKIN HYPOPIGMENTATION 175 0.0989
15 DRY SKIN 12767 0.0956
16 SERONEGATIVE ARTHRITIS 109 0.0951
17 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 60 0.0898
18 SKIN DISCOMFORT 235 0.0870
19 LUPUS VULGARIS 106 0.0841
20 SKIN SWELLING 729 0.0839
21 SKIN HYPERPIGMENTATION 679 0.0789
22 LYMPH NODE CALCIFICATION 15 0.0773
23 SKIN EXFOLIATION 5756 0.0682
24 ECTOPIC GASTRIC MUCOSA 2 0.0667
25 SECOND DEGREE CHEMICAL BURN OF SKIN 4 0.0667
26 CHOROIDITIS 24 0.0642
27 ERYTHEMA 12318 0.0599
28 RETINITIS 101 0.0584
29 RASH PAPULAR 1169 0.0521
30 SKIN TIGHTNESS 239 0.0508
31 CHEMICAL BURN 51 0.0442
32 DILATED PORES 4 0.0440
33 ADJUSTMENT DISORDER WITH DEPRESSED MOOD 90 0.0434
34 DEEP VEIN THROMBOSIS POSTOPERATIVE 76 0.0379
35 DISLOCATION OF VERTEBRA 84 0.0368
36 RASH MACULAR 1262 0.0361
37 SWOLLEN JOINT COUNT INCREASED 103 0.0323
38 DERMATITIS 650 0.0310
39 SKIN FISSURES 600 0.0307
40 SPERMATOZOA PROGRESSIVE MOTILITY DECREASED 5 0.0296
41 CHONDRITIS 5 0.0287
42 SCAR 479 0.0280
43 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 4811 0.0267
44 SCAB 292 0.0256
45 SKIN WARM 140 0.0240
46 SELF-CONSCIOUSNESS 6 0.0236
47 PERIORBITAL IRRITATION 8 0.0234
48 PATERNAL EXPOSURE BEFORE PREGNANCY 7 0.0230
49 RHEUMATIC FEVER 102 0.0229
50 EYELID EXFOLIATION 18 0.0228
51 BRONCHIAL WALL THICKENING 15 0.0209
52 SKIN INJURY 69 0.0208
53 UNDERDOSE 1489 0.0204
54 EYELID SKIN DRYNESS 23 0.0190
55 BONE EROSION 66 0.0186
56 SKIN REACTION 261 0.0185
57 RHEUMATOID FACTOR POSITIVE 106 0.0183
58 VOGT-KOYANAGI-HARADA DISEASE 4 0.0182
59 OVERDOSE 3784 0.0175
60 HYPOCHOLESTEROLAEMIA 6 0.0170
61 SKIN HAEMORRHAGE 252 0.0170
62 HYPERSENSITIVITY 3010 0.0162
63 SKIN DISCOLOURATION 741 0.0161
64 SUBCUTANEOUS DRUG ABSORPTION IMPAIRED 9 0.0160
65 JOINT DISLOCATION 167 0.0158
66 RASH ERYTHEMATOUS 737 0.0154
67 ECZEMA WEEPING 2 0.0153
68 CRIME 4 0.0152
69 WOUND INFECTION 158 0.0144
70 HYPERCHOLESTEROLAEMIA 136 0.0141
71 BURNS FIRST DEGREE 4 0.0140
72 ROSACEA 64 0.0137
73 EYELID IRRITATION 34 0.0135
74 SWELLING FACE 869 0.0133
75 SUNBURN 99 0.0133
76 POST INFLAMMATORY PIGMENTATION CHANGE 6 0.0132
77 SOFT TISSUE NECROSIS 9 0.0131
78 HYPERINSULINAEMIA 4 0.0131
79 PERIORBITAL INFLAMMATION 3 0.0130
80 MUSCLE INJURY 107 0.0129
81 DERMAL CYST 31 0.0126
82 JOINT RANGE OF MOTION DECREASED 169 0.0126
83 SKIN TEXTURE ABNORMAL 12 0.0125
84 WALKING AID USER 82 0.0124
85 EYELID RASH 12 0.0123
86 SWOLLEN JOINT COUNT 3 0.0120
87 ANTIDEPRESSANT DRUG LEVEL ABOVE THERAPEUTIC 3 0.0116
88 LUPUS-LIKE SYNDROME 104 0.0115
89 SEXUAL ABUSE 5 0.0113
90 PEMPHIGUS 139 0.0111
91 RASH 4782 0.0110
92 SPONDYLITIS 39 0.0107
93 HELICOBACTER INFECTION 109 0.0106
94 SKIN DISCHARGE 4 0.0105
95 DRUG INEFFECTIVE 13798 0.0105
96 GRIP STRENGTH DECREASED 92 0.0104
97 DRUG ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 74 0.0103
98 PERICARDITIS 173 0.0103
99 APPLICATION SITE ACNE 5 0.0102
100 DUODENAL ULCER PERFORATION 75 0.0101
101 SLEEP DISORDER DUE TO GENERAL MEDICAL CONDITION, INSOMNIA TYPE 65 0.0100
102 EYE ABSCESS 3 0.0098
103 BLISTER 544 0.0097
104 SKIN EROSION 31 0.0096
105 BREAST CANCER STAGE III 62 0.0096
106 EYE SWELLING 355 0.0095
107 FURUNCLE 73 0.0092
108 SPINAL FUSION SURGERY 37 0.0091
109 PRURITUS 3485 0.0091
110 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 63 0.0088
111 SKIN INDURATION 18 0.0087
112 RED BLOOD CELL SEDIMENTATION RATE INCREASED 96 0.0087
113 C-REACTIVE PROTEIN 8 0.0086
114 CHEMICAL INJURY 7 0.0086
115 FOLLICULITIS 89 0.0085
116 IRRITABLE BOWEL SYNDROME 181 0.0084
117 PRESCRIBED UNDERDOSE 163 0.0082
118 SKIN WRINKLING 22 0.0081
119 SCIATICA 129 0.0081
120 SWELLING OF EYELID 50 0.0080
121 PERIORAL DERMATITIS 5 0.0079
122 URTICARIA 1311 0.0078
123 PERIORBITAL SWELLING 44 0.0078
124 SKIN ULCER HAEMORRHAGE 3 0.0078
125 EXOSTOSIS 71 0.0078
126 SKIN INFECTION 86 0.0077
127 BURNS THIRD DEGREE 8 0.0076
128 STICKY SKIN 3 0.0075
129 MYOGLOBINURIA 4 0.0075
130 AUTOIMMUNE DISORDER 72 0.0074
131 BURSITIS INFECTIVE 4 0.0074
132 X-RAY ABNORMAL 13 0.0073
133 CHEMICAL BURNS OF EYE 2 0.0072
134 HIP ARTHROPLASTY 109 0.0071
135 JOINT STIFFNESS 176 0.0067
136 FOOT DEFORMITY 74 0.0067
137 APPLICATION SITE SWELLING 33 0.0066
138 APPLICATION SITE PAPULES 7 0.0066
139 HAND DEFORMITY 86 0.0066
140 WOUND 183 0.0065
141 SYNOVITIS 116 0.0064
142 SKIN ATROPHY 37 0.0064
143 AUTOIMMUNE MYOSITIS 3 0.0064
144 INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION 442 0.0062
145 KETONURIA 5 0.0061
146 PRESCRIBED OVERDOSE 115 0.0059
147 PERIORBITAL PAIN 5 0.0059
148 CAPILLARY FRAGILITY 3 0.0059
149 TYPE 2 DIABETES MELLITUS 194 0.0058
150 PULMONARY FIBROSIS 110 0.0057
151 PALMOPLANTAR KERATODERMA 4 0.0055
152 CONDITION AGGRAVATED 1676 0.0055
153 SKIN ABRASION 26 0.0055
154 EAR OPERATION 2 0.0054
155 DRUG CLEARANCE DECREASED 7 0.0054
156 DRUG TOLERANCE DECREASED 15 0.0053
157 THERAPEUTIC PRODUCT EFFECT DECREASED 238 0.0053
158 LOWER LIMB FRACTURE 100 0.0052
159 KNEE ARTHROPLASTY 109 0.0052
160 EYE BURNS 3 0.0051
161 PUSTULE 12 0.0051
162 LIVER FUNCTION TEST INCREASED 108 0.0050
163 LIP ERYTHEMA 4 0.0050
164 APPLICATION SITE DRYNESS 17 0.0050
165 SKIN BACTERIAL INFECTION 4 0.0050
166 FIBROMYALGIA 119 0.0049
167 LIVER INJURY 119 0.0048
168 SCRATCH 51 0.0048
169 CARBON MONOXIDE POISONING 2 0.0047
170 PATERNAL EXPOSURE DURING PREGNANCY 4 0.0046
171 PAPULE 32 0.0045
172 CONGESTIVE HEPATOPATHY 2 0.0045
173 ERYTHEMA OF EYELID 24 0.0044
174 LIP DRY 40 0.0044
175 RASH PUSTULAR 32 0.0044
176 IMPAIRED HEALING 143 0.0044
177 ENDOPHTHALMITIS 26 0.0043
178 DISCHARGE 6 0.0043
179 FACET JOINT SYNDROME 14 0.0043
180 OVERLAP SYNDROME 3 0.0043
181 ANAEMIA MACROCYTIC 9 0.0042
182 SKIN ULCER 109 0.0042
183 HEPATIC CIRRHOSIS 79 0.0042
184 APPLICATION SITE EXFOLIATION 17 0.0041
185 GLOSSODYNIA 92 0.0041
186 INCORRECT DOSAGE ADMINISTERED 20 0.0041
187 MILIARIA 7 0.0041
188 CHLAMYDIAL INFECTION 3 0.0040
189 BLEPHARAL PIGMENTATION 2 0.0040
190 APPLICATION SITE WARMTH 5 0.0039
191 JOINT DESTRUCTION 6 0.0039
192 ONYCHOLYSIS 6 0.0038
193 PSORIATIC ARTHROPATHY 154 0.0038
194 PRODUCT USE ISSUE 711 0.0038
195 OSTEOARTHRITIS 160 0.0038
196 THYROID HORMONES DECREASED 3 0.0037
197 SKIN MASS 25 0.0037
198 GAIT INABILITY 124 0.0037
199 EPHELIDES 2 0.0037
200 RESPIRATORY ALKALOSIS 6 0.0037
201 OSTEOPOROSIS 147 0.0036
202 UPPER RESPIRATORY TRACT INFECTION 163 0.0035
203 PRODUCT USE IN UNAPPROVED INDICATION 873 0.0035
204 PORPHYRIA ACUTE 5 0.0035
205 SYSTEMIC LUPUS ERYTHEMATOSUS 122 0.0034
206 PERIPHERAL VENOUS DISEASE 14 0.0034
207 ACUTE ABDOMEN 5 0.0034
208 ECZEMA 176 0.0034
209 ROAD TRAFFIC ACCIDENT 138 0.0033
210 STAPHYLOCOCCAL SKIN INFECTION 4 0.0033
211 THERMAL BURN 23 0.0032
212 APPLICATION SITE SCAR 4 0.0032
213 CORONARY ARTERY STENOSIS 16 0.0032
214 ADVERSE REACTION 42 0.0032
215 DISABILITY 62 0.0031
216 ONYCHOMADESIS 13 0.0031
217 LIP EXFOLIATION 4 0.0030
218 WHEEZING 178 0.0030
219 SKIN OEDEMA 3 0.0030
220 ACUTE LEFT VENTRICULAR FAILURE 2 0.0030
221 EYELIDS PRURITUS 9 0.0029
222 BURNS SECOND DEGREE 5 0.0028
223 CONNECTIVE TISSUE DISORDER 4 0.0028
224 DYSHIDROTIC ECZEMA 2 0.0028
225 EYE IRRITATION 158 0.0027
226 SKIN PAPILLOMA 11 0.0027
227 BLISTER RUPTURE 2 0.0027
228 RASH VESICULAR 13 0.0027
229 INFUSION SITE REACTION 8 0.0027
230 EAR INFECTION 71 0.0027
231 C-REACTIVE PROTEIN INCREASED 97 0.0027
232 OEDEMA 144 0.0027
233 PUSTULAR PSORIASIS 9 0.0026
234 ASEPTIC NECROSIS BONE 2 0.0026
235 BLEPHAROSPASM 16 0.0025
236 DRUG-INDUCED LIVER INJURY 79 0.0025
237 DELIRIUM 86 0.0025
238 EYELID PAIN 5 0.0025
239 DERMATITIS CONTACT 28 0.0025
240 APPLICATION SITE BURN 12 0.0024
241 ERYTHRODERMIC PSORIASIS 2 0.0024
242 INFUSION RELATED REACTION 161 0.0024
243 IMPAIRED SELF-CARE 5 0.0024
244 COVID-19 IMMUNISATION 2 0.0024
245 PRODUCT USED FOR UNKNOWN INDICATION 3 0.0024
246 SKIN WOUND 4 0.0024
247 CHAPPED LIPS 10 0.0023
248 APPLICATION SITE PARAESTHESIA 3 0.0023
249 UVEITIS 31 0.0023
250 ONYCHOMYCOSIS 10 0.0023
251 LIMB MASS 5 0.0023
252 GASTROINTESTINAL OEDEMA 4 0.0023
253 BLOOD CHOLESTEROL INCREASED 104 0.0022
254 NASAL OEDEMA 4 0.0022
255 MOBILITY DECREASED 158 0.0022
256 CORNEAL ABRASION 3 0.0022
257 C-REACTIVE PROTEIN ABNORMAL 14 0.0022
258 DISTURBANCE IN SEXUAL AROUSAL 2 0.0022
259 ACCIDENTAL DEATH 4 0.0022
260 PRODUCT EXPIRATION DATE ISSUE 3 0.0021
261 LIP SWELLING 69 0.0021
262 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 35 0.0021
263 EPIDERMAL NECROSIS 2 0.0021
264 LACRIMATION INCREASED 62 0.0021
265 DARK CIRCLES UNDER EYES 3 0.0020
266 INJURY 143 0.0020
267 COLON ADENOMA 2 0.0020
268 IMPETIGO 3 0.0020
269 HYPERPARATHYROIDISM SECONDARY 5 0.0020
270 SUSPECTED SUICIDE 9 0.0019
271 PURULENT DISCHARGE 8 0.0019
272 SKIN LESION 51 0.0019
273 OCULAR HYPERAEMIA 88 0.0019
274 APPLICATION SITE REACTION 13 0.0018
275 OESOPHAGEAL VARICES HAEMORRHAGE 4 0.0018
276 BLADDER DILATATION 2 0.0018
277 ACARODERMATITIS 2 0.0018
278 NAIL DISORDER 16 0.0018
279 BURSITIS 22 0.0018
280 WOUND SECRETION 7 0.0018
281 APPLICATION SITE URTICARIA 4 0.0018
282 SKIN HYPERTROPHY 5 0.0018
283 RASH PRURITIC 96 0.0018
284 JOINT LOCK 5 0.0018
285 VENTRICULAR SEPTAL DEFECT 10 0.0017
286 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 83 0.0017
287 INTRAOCULAR PRESSURE INCREASED 22 0.0017
288 DILATATION ATRIAL 2 0.0017
289 ACUTE LUNG INJURY 2 0.0017
290 SENSORY DISTURBANCE 27 0.0017
291 LIVE BIRTH 14 0.0017
292 APPLICATION SITE HYPERSENSITIVITY 2 0.0016
293 MUSCULOSKELETAL STIFFNESS 143 0.0016
294 HYPERKERATOSIS 9 0.0016
295 ULCER HAEMORRHAGE 11 0.0016
296 CONTUSION 156 0.0016
297 BREAST CANCER STAGE I 15 0.0016
298 CYST 20 0.0016
299 POISONING 20 0.0016
300 DERMATITIS ALLERGIC 20 0.0016
301 INFECTED SKIN ULCER 3 0.0016
302 BLOOD PRESSURE DIASTOLIC ABNORMAL 4 0.0016
303 HEPATIC ENZYME INCREASED 107 0.0016
304 BREAST CANCER STAGE II 13 0.0016
305 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 85 0.0015
306 PSORIASIS 202 0.0015
307 APPLICATION SITE PAIN 34 0.0015
308 APPLICATION SITE VESICLES 10 0.0015
309 OBSTRUCTIVE AIRWAYS DISORDER 17 0.0015
310 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 4 0.0015
311 PARAESTHESIA 234 0.0015
312 FUNGAL SKIN INFECTION 6 0.0015
313 ARTHROPATHY 82 0.0015
314 DERMATITIS PSORIASIFORM 3 0.0015
315 SUBCUTANEOUS ABSCESS 7 0.0015
316 INFECTION 209 0.0014
317 HANGOVER 5 0.0014
318 FEELING HOT 87 0.0014
319 EAR SWELLING 3 0.0014
320 VISUAL IMPAIRMENT 175 0.0014
321 SWELLING 131 0.0014
322 AMNESIA 91 0.0014
323 APPLICATION SITE SCAB 3 0.0014
324 MOUTH SWELLING 8 0.0014
325 SKIN LACERATION 15 0.0014
326 ELECTROCARDIOGRAM T WAVE INVERSION 3 0.0014
327 DANDRUFF 3 0.0014
328 SINUSITIS 139 0.0014
329 PRODUCT LOT NUMBER ISSUE 3 0.0014
330 APLASTIC ANAEMIA 7 0.0013
331 STOMATITIS 81 0.0013
332 SUSPECTED OFF LABEL USE 6 0.0013
333 DISCOMFORT 81 0.0013
334 SQUAMOUS CELL CARCINOMA OF SKIN 8 0.0013
335 REBOUND ACID HYPERSECRETION 4 0.0013
336 PROSTATITIS 4 0.0013
337 SKIN PLAQUE 11 0.0013
338 POOR QUALITY SLEEP 28 0.0013
339 COMPLETED SUICIDE 108 0.0013
340 NEPHROGENIC ANAEMIA 6 0.0013
341 EYELID OEDEMA 15 0.0013
342 ELECTROCARDIOGRAM T WAVE ABNORMAL 2 0.0013
343 HYPOAESTHESIA 190 0.0013
344 MUSCULAR WEAKNESS 142 0.0012
345 TACHYCARDIA 111 0.0012
346 APPLICATION SITE DISCOLOURATION 5 0.0012
347 BRADYARRHYTHMIA 2 0.0012
348 PRODUCT LABEL CONFUSION 7 0.0012
349 EYE PRURITUS 40 0.0012
350 EXPOSURE VIA INGESTION 3 0.0012
351 PRODUCT DISTRIBUTION ISSUE 11 0.0012
352 BILIARY DYSKINESIA 2 0.0012
353 PERIPHERAL SWELLING 181 0.0012
354 OEDEMA PERIPHERAL 142 0.0012
355 PERIPHERAL VASCULAR DISORDER 6 0.0012
356 ADVERSE EVENT 107 0.0012
357 CONTRAINDICATED PRODUCT ADMINISTERED 35 0.0012
358 APPLICATION SITE ERYTHEMA 30 0.0011
359 POOR QUALITY PRODUCT ADMINISTERED 12 0.0011
360 PULMONARY CONGESTION 15 0.0011
361 PHARYNGEAL SWELLING 11 0.0011
362 SKIN WEEPING 4 0.0011
363 LARYNGOSPASM 3 0.0011
364 MYOSITIS 10 0.0011
365 TOXICITY TO VARIOUS AGENTS 187 0.0011
366 BACK INJURY 12 0.0011
367 MONOCYTE COUNT INCREASED 4 0.0011
368 APPLICATION SITE RASH 15 0.0011
369 ERECTILE DYSFUNCTION 28 0.0011
370 EYE PAIN 61 0.0011
371 ASTHMA 122 0.0011
372 JOINT SWELLING 130 0.0011
373 THROAT TIGHTNESS 29 0.0011
374 OBESITY 17 0.0011
375 MATERNAL EXPOSURE TIMING UNSPECIFIED 4 0.0011
376 RHEUMATOID ARTHRITIS 117 0.0010
377 SKIN ODOUR ABNORMAL 4 0.0010
378 APPLICATION SITE PRURITUS 23 0.0010
379 GENERAL PHYSICAL HEALTH DETERIORATION 117 0.0010
380 PLATELET COUNT ABNORMAL 6 0.0010
381 EYE INJURY 3 0.0010
382 KERATITIS 3 0.0010
383 ARTHRITIS 77 0.0010
384 PIGMENTATION DISORDER 6 0.0010
385 LEG AMPUTATION 4 0.0010
386 PHOTOSENSITIVITY REACTION 16 0.0010
387 BRONCHITIS 71 0.0010
388 PULSELESS ELECTRICAL ACTIVITY 4 0.0010
389 WEIGHT INCREASED 214 0.0010
390 SELF-INJURIOUS IDEATION 4 0.0010
391 HYPERTENSION 201 0.0009
392 POLYARTHRITIS 5 0.0009
393 DYSPEPSIA 93 0.0009
394 GENERAL SYMPTOM 7 0.0009
395 VISUAL ACUITY REDUCED 31 0.0009
396 NASOPHARYNGITIS 170 0.0009
397 DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT 2 0.0009
398 HIGH DENSITY LIPOPROTEIN DECREASED 3 0.0009
399 BACTERIAL TEST POSITIVE 2 0.0009
400 BRONCHIECTASIS 6 0.0009
401 DRUG INTOLERANCE 85 0.0009
402 INTENTIONAL PRODUCT USE ISSUE 77 0.0009
403 SLEEP DISORDER 62 0.0009
404 BRONCHOPNEUMONIA 3 0.0009
405 MEMORY IMPAIRMENT 120 0.0009
406 SYNOVIAL CYST 4 0.0009
407 BREAKTHROUGH PAIN 2 0.0009
408 HYPERTRANSAMINASAEMIA 6 0.0009
409 ACUTE FEBRILE NEUTROPHILIC DERMATOSIS 2 0.0009
410 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 60 0.0008
411 DYSURIA 31 0.0008
412 EAR PAIN 16 0.0008
413 ABDOMINAL DISCOMFORT 138 0.0008
414 PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 5 0.0008
415 ASTHMATIC CRISIS 3 0.0008
416 EXPOSURE DURING PREGNANCY 51 0.0008
417 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 14 0.0008
418 COELIAC DISEASE 8 0.0008
419 WEIGHT DECREASED 225 0.0008
420 INFLAMMATION 41 0.0008
421 DRUG TOLERANCE 4 0.0008
422 PROSTATOMEGALY 3 0.0008
423 EXPOSURE VIA BREAST MILK 3 0.0008
424 BODY HEIGHT DECREASED 8 0.0007
425 ANAL FISSURE 4 0.0007
426 ADRENAL INSUFFICIENCY 9 0.0007
427 SELF-MEDICATION 3 0.0007
428 ONYCHOCLASIS 5 0.0007
429 CHEST PAIN 133 0.0007
430 PHARYNGEAL OEDEMA 11 0.0007
431 ANAL HAEMORRHAGE 2 0.0007
432 RENAL TUBULAR NECROSIS 7 0.0007
433 BREAST CANCER STAGE IV 2 0.0007
434 LOWER RESPIRATORY TRACT INFECTION 32 0.0007
435 PRODUCT SUPPLY ISSUE 5 0.0007
436 MICTURITION URGENCY 8 0.0007
437 HYPERVENTILATION 4 0.0007
438 METABOLIC ACIDOSIS 22 0.0007
439 PAIN IN EXTREMITY 202 0.0007
440 BLOOD CALCIUM INCREASED 6 0.0007
441 HEART RATE DECREASED 24 0.0007
442 ALOPECIA 133 0.0007
443 EYE DISCHARGE 7 0.0007
444 BURNING SENSATION 47 0.0007
445 MENINGITIS ASEPTIC 3 0.0007
446 HEPATITIS CHOLESTATIC 4 0.0007
447 BONE MARROW DISORDER 2 0.0007
448 DRUG TOXICITY 9 0.0007
449 HYPOGLYCAEMIA 32 0.0007
450 ACIDOSIS 5 0.0007
451 PRODUCTIVE COUGH 31 0.0006
452 LOCALISED OEDEMA 3 0.0006
453 HAEMOLYSIS 5 0.0006
454 APPLICATION SITE IRRITATION 8 0.0006
455 TASTE DISORDER 13 0.0006
456 GAIT DISTURBANCE 122 0.0006
457 CONFUSIONAL STATE 103 0.0006
458 PNEUMONIA 206 0.0006
459 SPINAL DISORDER 6 0.0006
460 BRAIN OEDEMA 8 0.0006
461 LOCAL SWELLING 11 0.0006
462 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 6 0.0006
463 NEUROTOXICITY 11 0.0006
464 MOVEMENT DISORDER 20 0.0006
465 DRY EYE 31 0.0006
466 FINGER DEFORMITY 3 0.0006
467 GALLBLADDER DISORDER 11 0.0006
468 INFLAMMATORY BOWEL DISEASE 6 0.0006
469 NODULE 8 0.0006
470 LUNG DISORDER 30 0.0006
471 IMMUNE SYSTEM DISORDER 8 0.0006
472 PRODUCT FORMULATION ISSUE 4 0.0006
473 SPINAL COMPRESSION FRACTURE 5 0.0006
474 ABDOMINAL TENDERNESS 3 0.0006
475 IMMUNODEFICIENCY 9 0.0006
476 PROTEIN URINE PRESENT 3 0.0006
477 RENAL DISORDER 28 0.0006
478 PNEUMONIA ASPIRATION 15 0.0006
479 COAGULOPATHY 10 0.0006
480 NIGHT SWEATS 19 0.0006
481 PRODUCT LABEL ISSUE 4 0.0006
482 B-CELL LYMPHOMA 2 0.0006
483 ACCIDENT 7 0.0006
484 ELECTROCARDIOGRAM QRS COMPLEX PROLONGED 3 0.0006
485 ANKLE FRACTURE 9 0.0006
486 DRY MOUTH 47 0.0006
487 ORAL DISCOMFORT 8 0.0006
488 DERMATITIS EXFOLIATIVE GENERALISED 2 0.0006
489 CAROTID ARTERY STENOSIS 2 0.0006
490 TUMOUR LYSIS SYNDROME 5 0.0006
491 ADVERSE DRUG REACTION 51 0.0006
492 SKIN CANCER 12 0.0006
493 BEHAVIOUR DISORDER 3 0.0006
494 CHEILITIS 3 0.0006
495 END STAGE RENAL DISEASE 10 0.0005
496 ASPIRATION 6 0.0005
497 BLOOD PHOSPHORUS DECREASED 2 0.0005
498 DECREASED APPETITE 126 0.0005
499 VOMITING 255 0.0005
500 PRODUCT PHYSICAL CONSISTENCY ISSUE 3 0.0005
501 EXPIRED PRODUCT ADMINISTERED 18 0.0005
502 NECROSIS 3 0.0005
503 ORAL CANDIDIASIS 7 0.0005
504 AUTOIMMUNE THYROIDITIS 2 0.0005
505 NASAL CONGESTION 31 0.0005
506 EYE INFLAMMATION 5 0.0005
507 CATARACT 31 0.0005
508 DEVICE DEFECTIVE 9 0.0005
509 DIFFUSE LARGE B-CELL LYMPHOMA 4 0.0005
510 LIMB DISCOMFORT 16 0.0005
511 POST PROCEDURAL HAEMORRHAGE 6 0.0005
512 HYPOALBUMINAEMIA 4 0.0005
513 PYREXIA 178 0.0005
514 PRODUCT COMPLAINT 13 0.0005
515 HYPOVOLAEMIA 3 0.0005
516 THERAPEUTIC RESPONSE DECREASED 31 0.0005
517 LYMPHOCYTE COUNT DECREASED 9 0.0005
518 ACUTE RESPIRATORY DISTRESS SYNDROME 9 0.0005
519 HEPATOMEGALY 5 0.0005
520 HYPOMAGNESAEMIA 7 0.0005
521 CARDIO-RESPIRATORY ARREST 21 0.0005
522 ABSCESS 8 0.0005
523 AZOTAEMIA 2 0.0005
524 BLOOD PRESSURE INADEQUATELY CONTROLLED 3 0.0005
525 BLEPHARITIS 2 0.0005
526 CELLULITIS 25 0.0005
527 MATERNAL EXPOSURE DURING PREGNANCY 44 0.0005
528 WRONG TECHNIQUE IN DEVICE USAGE PROCESS 23 0.0005
529 BACK DISORDER 8 0.0005
530 DRY THROAT 5 0.0005
531 EPILEPSY 15 0.0005
532 MENISCUS INJURY 3 0.0005
533 STAPHYLOCOCCAL INFECTION 16 0.0005
534 TREATMENT FAILURE 40 0.0005
535 HAIR COLOUR CHANGES 6 0.0005
536 BLOOD PRESSURE DECREASED 32 0.0005
537 PRE-EXISTING CONDITION IMPROVED 3 0.0005
538 GASTROINTESTINAL DISORDER 43 0.0005
539 TENDERNESS 5 0.0005
540 PALLOR 13 0.0005
541 DYSPNOEA 270 0.0005
542 FRACTURE 9 0.0005
543 ANXIETY 135 0.0005
544 BLOOD URINE PRESENT 9 0.0005
545 ABSCESS LIMB 2 0.0005
546 PRURITUS GENERALISED 10 0.0005
547 BLOOD PRESSURE SYSTOLIC INCREASED 9 0.0005
548 SYNCOPE 46 0.0005
549 POLYP 3 0.0005
550 PRODUCT PREPARATION ISSUE 3 0.0005
551 SKIN DISORDER 15 0.0004
552 CHOLECYSTITIS CHRONIC 3 0.0004
553 POST-TRAUMATIC STRESS DISORDER 3 0.0004
554 QUALITY OF LIFE DECREASED 6 0.0004
555 HAEMOLYTIC ANAEMIA 4 0.0004
556 JAUNDICE 12 0.0004
557 THERAPY NON-RESPONDER 20 0.0004
558 TACHYPNOEA 6 0.0004
559 CRYING 16 0.0004
560 IMPAIRED DRIVING ABILITY 5 0.0004
561 DEPRESSION 100 0.0004
562 HIDRADENITIS 4 0.0004
563 INFARCTION 3 0.0004
564 CROHN'S DISEASE 3 0.0004
565 RESPIRATORY ARREST 12 0.0004
566 ARTHRITIS INFECTIVE 2 0.0004
567 FLANK PAIN 4 0.0004
568 SQUAMOUS CELL CARCINOMA 4 0.0004
569 RESPIRATORY TRACT INFECTION 11 0.0004
570 RENAL FAILURE 56 0.0004
571 CHRONIC LYMPHOCYTIC LEUKAEMIA 2 0.0004
572 CHRONIC KIDNEY DISEASE 32 0.0004
573 PRODUCT PRESCRIBING ERROR 10 0.0004
574 ENDOMETRIOSIS 2 0.0004
575 SWOLLEN TONGUE 13 0.0004
576 FLUID OVERLOAD 6 0.0004
577 RASH MACULO-PAPULAR 9 0.0004
578 RESPIRATORY DISORDER 12 0.0004
579 SECRETION DISCHARGE 5 0.0004
580 HEPATIC FAILURE 12 0.0004
581 HYPOAESTHESIA ORAL 6 0.0004
582 PAROSMIA 3 0.0004
583 NECK PAIN 22 0.0004
584 FUNGAL INFECTION 13 0.0004
585 HYPOKALAEMIA 18 0.0004
586 MIGRAINE 37 0.0004
587 BENIGN PROSTATIC HYPERPLASIA 2 0.0004
588 OSTEOMYELITIS 7 0.0004
589 ACUTE GENERALISED EXANTHEMATOUS PUSTULOSIS 3 0.0004
590 PAIN 236 0.0004
591 LIVER DISORDER 17 0.0004
592 ARTHRALGIA 159 0.0004
593 MUSCULOSKELETAL PAIN 20 0.0004
594 ARTERIAL OCCLUSIVE DISEASE 3 0.0004
595 ANAPHYLACTIC REACTION 21 0.0004
596 ACUTE KIDNEY INJURY 58 0.0004
597 THROAT IRRITATION 17 0.0004
598 RENAL PAIN 4 0.0004
599 BACTERIAL INFECTION 7 0.0004
600 MALIGNANT MELANOMA 5 0.0004
601 FRUSTRATION TOLERANCE DECREASED 3 0.0004
602 BIPOLAR DISORDER 4 0.0004
603 OESOPHAGITIS 4 0.0004
604 ACUTE CORONARY SYNDROME 3 0.0004
605 ILL-DEFINED DISORDER 22 0.0004
606 HEADACHE 227 0.0004
607 EOSINOPHIL COUNT INCREASED 3 0.0004
608 DRUG USE DISORDER 3 0.0004
609 MULTIPLE ORGAN DYSFUNCTION SYNDROME 10 0.0004
610 BRONCHOSPASM 5 0.0004
611 PREGNANCY 7 0.0003
612 TINNITUS 16 0.0003
613 EXERCISE TOLERANCE DECREASED 2 0.0003
614 MADAROSIS 4 0.0003
615 GROIN PAIN 3 0.0003
616 SPLENOMEGALY 4 0.0003
617 SPINAL PAIN 4 0.0003
618 HEAD DISCOMFORT 6 0.0003
619 ENERGY INCREASED 2 0.0003
620 DIZZINESS 169 0.0003
621 CARDIOTOXICITY 3 0.0003
622 FACIAL PAIN 3 0.0003
623 GASTROOESOPHAGEAL REFLUX DISEASE 27 0.0003
624 EYE DISORDER 11 0.0003
625 OROPHARYNGEAL DISCOMFORT 3 0.0003
626 VIRAL INFECTION 11 0.0003
627 NOCTURIA 4 0.0003
628 PANIC ATTACK 12 0.0003
629 VISION BLURRED 45 0.0003
630 MENTAL STATUS CHANGES 9 0.0003
631 MUSCULOSKELETAL CHEST PAIN 5 0.0003
632 PRODUCT DISPENSING ERROR 7 0.0003
633 DIARRHOEA HAEMORRHAGIC 3 0.0003
634 BASAL CELL CARCINOMA 5 0.0003
635 PHOTOPHOBIA 6 0.0003
636 LACERATION 3 0.0003
637 ARTERIOSCLEROSIS 3 0.0003
638 GASTRIC ULCER 6 0.0003
639 BLOOD LACTATE DEHYDROGENASE INCREASED 5 0.0003
640 HEPATITIS 8 0.0003
641 DRUG ABUSE 26 0.0003
642 SNEEZING 7 0.0003
643 ACUTE RESPIRATORY FAILURE 6 0.0003
644 MYDRIASIS 4 0.0003
645 RHABDOMYOLYSIS 13 0.0003
646 ANAPHYLACTIC SHOCK 8 0.0003
647 CARDIAC FLUTTER 2 0.0003
648 HIATUS HERNIA 4 0.0003
649 DEAFNESS 8 0.0003
650 BACK PAIN 71 0.0003
651 GASTRITIS 8 0.0003
652 LIGAMENT SPRAIN 3 0.0003
653 SPINAL FRACTURE 6 0.0003
654 HYPOTHERMIA 3 0.0003
655 CIRCULATORY COLLAPSE 5 0.0003
656 IMPAIRED GASTRIC EMPTYING 4 0.0003
657 INSOMNIA 78 0.0003
658 RIB FRACTURE 6 0.0003
659 TEMPERATURE INTOLERANCE 3 0.0003
660 LOCALISED INFECTION 7 0.0003
661 HUNGER 4 0.0003
662 WEIGHT FLUCTUATION 3 0.0003
663 PRODUCT ODOUR ABNORMAL 3 0.0003
664 MASS 4 0.0003
665 INJECTION SITE URTICARIA 7 0.0003
666 DUODENAL ULCER 2 0.0003
667 CLOSTRIDIUM DIFFICILE COLITIS 3 0.0003
668 LYMPHADENOPATHY 10 0.0003
669 COGNITIVE DISORDER 13 0.0003
670 DERMATITIS BULLOUS 2 0.0003
671 TOOTHACHE 5 0.0003
672 CLOSTRIDIUM DIFFICILE INFECTION 6 0.0003
673 UNRESPONSIVE TO STIMULI 7 0.0003
674 GAMMA-GLUTAMYLTRANSFERASE INCREASED 6 0.0003
675 STEVENS-JOHNSON SYNDROME 6 0.0003
676 ARTHROPOD BITE 2 0.0003
677 COLITIS ULCERATIVE 12 0.0003
678 MIDDLE INSOMNIA 5 0.0003
679 HAEMORRHAGE INTRACRANIAL 4 0.0003
680 TUBULOINTERSTITIAL NEPHRITIS 5 0.0003
681 EYE INFECTION 3 0.0003
682 STATUS EPILEPTICUS 3 0.0003
683 INTENTIONAL OVERDOSE 17 0.0003
684 CHOLECYSTECTOMY 3 0.0003
685 DIABETES MELLITUS 20 0.0003
686 NEPHROLITHIASIS 12 0.0003
687 MUSCLE TWITCHING 6 0.0003
688 NAUSEA 206 0.0003
689 LEUKOPENIA 13 0.0003
690 THYROID DISORDER 4 0.0003
691 FREQUENT BOWEL MOVEMENTS 7 0.0003
692 LOSS OF CONSCIOUSNESS 33 0.0003
693 EJECTION FRACTION DECREASED 4 0.0003
694 HYPERKALAEMIA 9 0.0003
695 NEOPLASM MALIGNANT 17 0.0003
696 AFFECTIVE DISORDER 2 0.0003
697 CHEST DISCOMFORT 26 0.0003
698 SEPTIC SHOCK 11 0.0003
699 ILLNESS 26 0.0003
700 BLOOD ALBUMIN DECREASED 2 0.0003
701 CHOLECYSTITIS 3 0.0003
702 ULCER 4 0.0003
703 ATRIAL FLUTTER 2 0.0003
704 BLOOD PRESSURE FLUCTUATION 6 0.0002
705 CYTOKINE RELEASE SYNDROME 5 0.0002
706 CHRONIC OBSTRUCTIVE PULMONARY DISEASE 13 0.0002
707 ABDOMINAL PAIN UPPER 51 0.0002
708 SCHIZOPHRENIA 3 0.0002
709 DRUG INTERACTION 39 0.0002
710 THERAPEUTIC RESPONSE UNEXPECTED 11 0.0002
711 ASPHYXIA 2 0.0002
712 CARDIOMEGALY 3 0.0002
713 TENDON RUPTURE 3 0.0002
714 HYPERCALCAEMIA 3 0.0002
715 DYSPHAGIA 23 0.0002
716 EXTRAPYRAMIDAL DISORDER 6 0.0002
717 AGEUSIA 6 0.0002
718 COVID-19 42 0.0002
719 FATIGUE 185 0.0002
720 ACUTE MYOCARDIAL INFARCTION 7 0.0002
721 DIARRHOEA 153 0.0002
722 CANDIDA INFECTION 4 0.0002
723 OFF LABEL USE 207 0.0002
724 FLUID RETENTION 12 0.0002
725 RENAL INJURY 7 0.0002
726 IMPAIRED WORK ABILITY 5 0.0002
727 MEDICATION ERROR 13 0.0002
728 HAEMATURIA 8 0.0002
729 INFUSION SITE PAIN 3 0.0002
730 RECTAL HAEMORRHAGE 10 0.0002
731 INJECTION SITE REACTION 16 0.0002
732 PARANOIA 4 0.0002
733 COMA 11 0.0002
734 FAECES DISCOLOURED 5 0.0002
735 MUSCLE SPASMS 42 0.0002
736 ABDOMINAL PAIN 53 0.0002
737 METASTASES TO LIVER 4 0.0002
738 BLOOD TRIGLYCERIDES INCREASED 4 0.0002
739 ANGIOEDEMA 10 0.0002
740 FEMUR FRACTURE 7 0.0002
741 THIRST 4 0.0002
742 GASTROENTERITIS VIRAL 4 0.0002
743 LIMB INJURY 6 0.0002
744 PROSTATIC SPECIFIC ANTIGEN INCREASED 3 0.0002
745 BLOOD THYROID STIMULATING HORMONE INCREASED 2 0.0002
746 HYPERHIDROSIS 28 0.0002
747 LACTIC ACIDOSIS 7 0.0002
748 BLOOD PRESSURE INCREASED 33 0.0002
749 EMOTIONAL DISTRESS 26 0.0002
750 THINKING ABNORMAL 4 0.0002
751 HEPATIC FUNCTION ABNORMAL 8 0.0002
752 INCORRECT DRUG ADMINISTRATION DURATION 6 0.0002
753 SEASONAL ALLERGY 3 0.0002
754 ALANINE AMINOTRANSFERASE INCREASED 13 0.0002
755 HYPOCALCAEMIA 4 0.0002
756 COUGH 59 0.0002
757 FALL 70 0.0002
758 GLAUCOMA 4 0.0002
759 BRADYCARDIA 11 0.0002
760 APATHY 3 0.0002
761 PRESYNCOPE 5 0.0002
762 INTENTIONAL PRODUCT MISUSE 18 0.0002
763 OROPHARYNGEAL PAIN 19 0.0002
764 HAEMORRHOIDS 4 0.0002
765 ENCEPHALOPATHY 5 0.0002
766 CARDIAC DISORDER 19 0.0002
767 DEPRESSED LEVEL OF CONSCIOUSNESS 8 0.0002
768 COLON CANCER 3 0.0002
769 BRAIN INJURY 2 0.0002
770 ECONOMIC PROBLEM 3 0.0002
771 OSTEOPENIA 3 0.0002
772 FEEDING DISORDER 4 0.0002
773 ELECTROCARDIOGRAM QT PROLONGED 7 0.0002
774 PRODUCT STORAGE ERROR 17 0.0002
775 CARDIAC ARREST 16 0.0002
776 RASH GENERALISED 5 0.0002
777 THERAPY PARTIAL RESPONDER 3 0.0002
778 PULMONARY HYPERTENSION 4 0.0002
779 RESTLESSNESS 7 0.0002
780 ANHEDONIA 5 0.0002
781 HALLUCINATION, VISUAL 4 0.0002
782 PANCREATITIS 10 0.0002
783 INTESTINAL OBSTRUCTION 7 0.0002
784 DECREASED ACTIVITY 2 0.0002
785 MUSCLE TIGHTNESS 3 0.0002
786 COLITIS 7 0.0002
787 INCORRECT PRODUCT ADMINISTRATION DURATION 4 0.0002
788 ACCIDENTAL EXPOSURE TO PRODUCT 19 0.0002
789 TREATMENT NONCOMPLIANCE 10 0.0002
790 BLOOD GLUCOSE FLUCTUATION 2 0.0002
791 GENERALISED TONIC-CLONIC SEIZURE 3 0.0002
792 DRUG LEVEL INCREASED 3 0.0002
793 DEHYDRATION 24 0.0002
794 TOOTH DISORDER 4 0.0002
795 FEELING COLD 5 0.0002
796 HYPOTENSION 36 0.0002
797 NEUROPATHY PERIPHERAL 17 0.0002
798 OXYGEN SATURATION DECREASED 10 0.0002
799 BLOOD CALCIUM DECREASED 2 0.0002
800 MUSCULOSKELETAL DISCOMFORT 3 0.0002
801 BLOOD CREATINE PHOSPHOKINASE INCREASED 5 0.0002
802 MULTI-ORGAN FAILURE 3 0.0002
803 ABDOMINAL DISTENSION 18 0.0002
804 HAEMORRHAGE 18 0.0002
805 NEEDLE ISSUE 5 0.0002
806 MALAISE 75 0.0002
807 DERMATITIS ATOPIC 9 0.0002
808 DIABETES MELLITUS INADEQUATE CONTROL 3 0.0002
809 COVID-19 PNEUMONIA 2 0.0002
810 DISEASE RECURRENCE 8 0.0002
811 POLLAKIURIA 7 0.0002
812 FLUSHING 17 0.0002
813 RENAL IMPAIRMENT 14 0.0002
814 DRUG EFFECT INCOMPLETE 6 0.0002
815 SEIZURE 19 0.0002
816 ATRIAL FIBRILLATION 16 0.0002
817 URINARY TRACT INFECTION 28 0.0002
818 OSTEONECROSIS OF JAW 4 0.0002
819 DYSGEUSIA 12 0.0002
820 BLOOD ALKALINE PHOSPHATASE INCREASED 4 0.0002
821 DYSPNOEA EXERTIONAL 6 0.0002
822 BLOOD SODIUM DECREASED 3 0.0002
823 HAEMATEMESIS 4 0.0002
824 CYSTITIS 5 0.0002
825 LETHARGY 9 0.0002
826 WHITE BLOOD CELL COUNT INCREASED 6 0.0002
827 POST PROCEDURAL COMPLICATION 3 0.0002
828 DRUG PRESCRIBING ERROR 3 0.0002
829 ANOREXIA 2 0.0002
830 PRODUCT QUALITY ISSUE 21 0.0002
831 DYSPHONIA 9 0.0002
832 PALPITATIONS 18 0.0002
833 BEDRIDDEN 2 0.0002
834 ACTIVITIES OF DAILY LIVING IMPAIRED 3 0.0002
835 SINUS DISORDER 3 0.0002
836 HEART RATE INCREASED 15 0.0002
837 BLOOD PRESSURE ABNORMAL 3 0.0002
838 URINARY RETENTION 5 0.0001
839 ABORTION SPONTANEOUS 6 0.0001
840 IRRITABILITY 9 0.0001
841 ASTHENIA 56 0.0001
842 PRODUCT ADMINISTRATION ERROR 3 0.0001
843 PLEURAL EFFUSION 9 0.0001
844 BLINDNESS 6 0.0001
845 FEELING ABNORMAL 35 0.0001
846 HALLUCINATION 11 0.0001
847 TOOTH LOSS 3 0.0001
848 DIVERTICULITIS 4 0.0001
849 APHONIA 2 0.0001
850 DISSEMINATED INTRAVASCULAR COAGULATION 2 0.0001
851 RENAL FAILURE ACUTE 6 0.0001
852 CARDIOGENIC SHOCK 2 0.0001
853 COMPLICATION ASSOCIATED WITH DEVICE 2 0.0001
854 CARDIAC FAILURE 11 0.0001
855 DYSSTASIA 4 0.0001
856 ACCIDENTAL OVERDOSE 5 0.0001
857 BONE PAIN 8 0.0001
858 THERAPY CESSATION 7 0.0001
859 HAEMOGLOBIN DECREASED 14 0.0001
860 DEVICE DIFFICULT TO USE 9 0.0001
861 LABORATORY TEST ABNORMAL 4 0.0001
862 FOETAL EXPOSURE DURING PREGNANCY 11 0.0001
863 URINARY INCONTINENCE 4 0.0001
864 DRUG EFFECT LESS THAN EXPECTED 2 0.0001
865 SOMNOLENCE 27 0.0001
866 ORAL PAIN 3 0.0001
867 HEART RATE IRREGULAR 3 0.0001
868 HOT FLUSH 10 0.0001
869 ASPARTATE AMINOTRANSFERASE INCREASED 7 0.0001
870 DEVICE FAILURE 2 0.0001
871 SUICIDAL IDEATION 12 0.0001
872 PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME 3 0.0001
873 BRAIN FOG 2 0.0001
874 ANAEMIA 24 0.0001
875 SEPSIS 14 0.0001
876 MENTAL IMPAIRMENT 3 0.0001
877 FLATULENCE 7 0.0001
878 BLOOD POTASSIUM INCREASED 2 0.0001
879 NEUTROPHIL COUNT DECREASED 5 0.0001
880 DEVICE ISSUE 11 0.0001
881 OSTEONECROSIS 4 0.0001
882 TREMOR 20 0.0001
883 AGGRESSION 6 0.0001
884 BLOOD UREA INCREASED 2 0.0001
885 ANGER 4 0.0001
886 DRUG RESISTANCE 3 0.0001
887 GASTRIC DISORDER 4 0.0001
888 HYPOACUSIS 5 0.0001
889 PHARMACEUTICAL PRODUCT COMPLAINT 3 0.0001
890 SUICIDE ATTEMPT 7 0.0001
891 DEVICE MALFUNCTION 8 0.0001
892 COLD SWEAT 2 0.0001
893 INJECTION SITE ERYTHEMA 14 0.0001
894 PULMONARY OEDEMA 5 0.0001
895 WHITE BLOOD CELL COUNT DECREASED 12 0.0001
896 WRONG TECHNIQUE IN DRUG USAGE PROCESS 4 0.0001
897 CONSTIPATION 24 0.0001
898 BONE DISORDER 2 0.0001
899 AGITATION 8 0.0001
900 ABNORMAL DREAMS 3 0.0001
901 RHINORRHOEA 7 0.0001
902 BLOOD GLUCOSE ABNORMAL 2 0.0001
903 PROCEDURAL PAIN 3 0.0001
904 CONJUNCTIVITIS 2 0.0001
905 DEEP VEIN THROMBOSIS 7 0.0001
906 INFLUENZA 12 0.0001
907 PAIN IN JAW 3 0.0001
908 INTENTIONAL DOSE OMISSION 3 0.0001
909 CHOLESTASIS 2 0.0001
910 ERUCTATION 2 0.0001
911 DRUG WITHDRAWAL SYNDROME 9 0.0001
912 CHOKING 2 0.0001
913 DISORIENTATION 4 0.0001
914 MYALGIA 17 0.0001
915 APHASIA 3 0.0001
916 CORONARY ARTERY DISEASE 3 0.0001
917 THROMBOCYTOPENIA 11 0.0001
918 BODY TEMPERATURE INCREASED 2 0.0001
919 DRUG ADMINISTRATION ERROR 3 0.0001
920 NERVOUS SYSTEM DISORDER 3 0.0001
921 SPEECH DISORDER 5 0.0001
922 HEAD INJURY 3 0.0001
923 HYPOTHYROIDISM 3 0.0001
924 EPISTAXIS 7 0.0001
925 DISTURBANCE IN ATTENTION 5 0.0001
926 UNEVALUABLE EVENT 7 0.0001
927 ALTERED STATE OF CONSCIOUSNESS 2 0.0001
928 VAGINAL HAEMORRHAGE 4 0.0001
929 MYOCARDIAL INFARCTION 16 0.0001
930 CHOLELITHIASIS 3 0.0001
931 THERAPEUTIC RESPONSE SHORTENED 3 0.0001
932 CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 3 0.0001
933 CHROMATURIA 2 0.0001
934 DRUG EXPOSURE DURING PREGNANCY 3 0.0001
935 MALIGNANT NEOPLASM PROGRESSION 9 0.0001
936 NIGHTMARE 3 0.0001
937 CHILLS 10 0.0001
938 SURGERY 5 0.0001
939 HYPOXIA 3 0.0001
940 DRUG DOSE OMISSION 14 0.0001
941 DISEASE PROGRESSION 10 0.0001
942 BLOOD GLUCOSE DECREASED 4 0.0001
943 NO ADVERSE EVENT 15 0.0001
944 CEREBROVASCULAR ACCIDENT 14 0.0001
945 HYPERGLYCAEMIA 3 0.0001
946 VERTIGO 5 0.0001
947 ABASIA 2 0.0001
948 CARDIOVASCULAR DISORDER 2 0.0001
949 HOSPITALISATION 12 0.0001
950 EXPOSURE VIA SKIN CONTACT 2 0.0001
951 NERVOUSNESS 4 0.0001
952 ABNORMAL BEHAVIOUR 3 0.0001
953 DEPRESSED MOOD 4 0.0001
954 FEBRILE NEUTROPENIA 5 0.0001
955 PLATELET COUNT DECREASED 8 0.0001
956 CARDIAC FAILURE CONGESTIVE 6 0.0001
957 INCORRECT DOSE ADMINISTERED 17 0.0001
958 BLOOD GLUCOSE INCREASED 14 0.0001
959 PANCYTOPENIA 4 0.0001
960 HYPONATRAEMIA 4 0.0001
961 BALANCE DISORDER 6 0.0001
962 ASCITES 2 0.0001
963 EMOTIONAL DISORDER 2 0.0001
964 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 13 0.0001
965 BONE DENSITY DECREASED 2 0.0001
966 ARRHYTHMIA 3 0.0001
967 MULTIPLE SCLEROSIS 3 0.0001
968 INTERSTITIAL LUNG DISEASE 3 0.0001
969 PRODUCT DOSE OMISSION 4 0.0001
970 BLOOD CREATININE INCREASED 4 0.0001
971 PRODUCT DOSE OMISSION ISSUE 18 0.0001
972 DEATH 52 0.0001
973 GASTROINTESTINAL HAEMORRHAGE 5 0.0001
974 RESPIRATORY FAILURE 4 0.0001
975 HAEMATOCHEZIA 3 0.0001
976 PULMONARY EMBOLISM 5 0.0001
977 HERPES ZOSTER 3 0.0001
978 PRODUCT SUBSTITUTION ISSUE 3 0.0001
979 BLADDER CANCER 3 0.0001
980 INJECTION SITE BRUISING 4 0.0001
981 DYSKINESIA 2 0.0000
982 INJECTION SITE PAIN 15 0.0000
983 INFLUENZA LIKE ILLNESS 4 0.0000
984 THERAPY INTERRUPTED 3 0.0000
985 PROSTATE CANCER 3 0.0000
986 DRUG EFFECT DECREASED 2 0.0000
987 CONVULSION 2 0.0000
988 BREAST CANCER 3 0.0000
989 NEUTROPENIA 4 0.0000
990 DRUG DEPENDENCE 4 0.0000